RADIESSE Injection in Perioral and Marionette Lines

Inclusion Criteria: 1. At the time of consent, women between the ages of 18 and 80 years old; 2. Patient requires lower face treatment (perioral/marionette region) with RADIESSE; 3. Willingness to comply with study requirements; 4. Provide written consent; 5. Patient has a rating of 2 or 3 at Baseline on the Merz Marionette Grading Scale, as per the investigator; 6. Accepted the obligation not to receive any other facial procedures through the follow-up; 7. Understood and accepted the obligation and would be logistically able to appear for all scheduled follow-up visits; 8. No previous facial fillers for a period of 12 months prior to this study; 9. No previous facial fillers in the lower face for 18 months prior to this study. Exclusion Criteria: 1. Current Pregnancy or lactation \[sexually active women of childbearing age must agree to use medically acceptable methods of contraception for the duration of this study (e.g., oral contraceptives, condoms, intrauterine device, shot/injection, patch)\]; 2. Hypersensitivity to RADIESSE, calcium hydroxylpatite filler or local anesthetics; 3. Patient has received any lower face treatment during the last 12 months, or neuromodulator in the last 6 months; 4. Patient has received mentalis muscle injections of any kind (BoNT-A or fillers) in the last 6 months; 5. Patients meeting any official RADIESSE contra-indications; 6. Patients presenting with porphyria; 7. Inability to comply with follow-up and abstain from facial injections during the study period; 8. Heavy smokers, classified as smoking more than 12 cigarettes per day; 9. History of severe or multiple allergies manifested by anaphylaxis; 10. Previous tissue revitalization therapy in the treatment area within 6 months before treatment with laser or light, mesotherapy, radiofrequency, ultrasound, cryotherapy, chemical peeling, or dermabrasion; 11. Previous surgery including aesthetic facial surgical therapy or liposuction, piercing, or tattoos in the treatment area; 12. History or presence of any disease or lesion near or at the treatment area, including inflammation, active or chronic infection, including in the mouth, dentals, head and neck region; 13. Facial psoriasis, eczema, acne, rosacea, perioral dermatitis and herpes zoster in the treatment area; 14. Cancer or precancer in the treatment area, e.g. actinic keratosis; 15. History of bleeding disorders or treatment with thrombolytics, anticoagulants, or inhibitors of platelet aggregation (e.g. Aspirin or other non-steroid anti-inflammatory drugs \[NSAIDs\]), within 2 weeks before treatment; 16. Patients using immunosuppressants; 17. Patients with a tendency to form hypertrophic scars or any other healing disorders; 18. Patients with known hypersensitivity to lidocaine or agents structurally related to amide type local anaesthetics (e.g., certain anti-arrhythmics); 19. Patients administered dental block or topical administration of lidocaine; 20. Patients with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction.